Biotech and pharmaceutical firms are optimistic about a second generation of PI3K drugs, aiming to overcome the previous issues that curtailed their success. The focus of the new drugs will be on overall survival, given the disappointing results of the first generation. The toxicity of these first-generation drugs is thought to have influenced their lack of survival benefit, prompting the FDA to request further early-stage dose-finding studies. The potential of the next generation PI3K inhibitors lies in their function as immunotherapies for both solid and hematological tumors and might be combined with other treatments for enhanced effect.
Jennifer Williams named Vice President, Information Security at HOOPP
Jennifer Williams has been named the new Vice President of Information Security at HOOPP. She brings a wealth of experience and expertise to the role,
